التفاصيل البيبلوغرافية
| العنوان: |
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189 |
| المؤلفون: |
Gadgeel, Shirish, Grey, Jhanelle, Rizzo, Maria Teresa, Peterson, Patrick, Kim, Jongseok, RodrÃguez-Abreu, Delvys |
| المصدر: |
Hematology/Oncology Meeting Abstracts |
| بيانات النشر: |
Henry Ford Health Scholarly Commons |
| سنة النشر: |
2021 |
| المجموعة: |
Henry Ford Health System Scholarly Commons |
| مصطلحات موضوعية: |
endogenous compound, pembrolizumab, pemetrexed, placebo, programmed death 1 ligand 1, adult, cancer patient, cancer size, clinical trial, conference abstract, controlled study, distant metastasis, drug efficacy, drug therapy, female, gene expression, health care quality, human, major clinical study, male, non small cell lung cancer, organ systems, protein expression, randomized controlled trial, vascular guide wire, Hematology |
| الوصف: |
Background: Pemetrexed (pem) and platinum (plat) plus pembrolizumab (pembro) showed clinical improvement in metastatic nonsquamous (NSQ) non-small-cell lung cancer (NSCLC). The aim of this analysis was to assess the clinical benefit of pem+plat+pembro in patients by tumor burden at baseline. Methods: The intention-to-treat population was analysed. Patients were randomized pem+plat+pembro (n=410) or pem+plat+placebo (n=206). The data cut-off date was May 20, 2019. OS, PFS, PFS-2, and ORR were evaluated by Kaplan-Meier and univariate Cox methods within subgroups identified by extent of distant metastasis (M1a vs. M1b), median number (≤3 vs. >3) of organ systems with lesions, and severity score of patient-reported symptoms (below median vs. above median) at baseline. These subgroup analyses were also replicated within PD-L1 TPS subgroups (<1%, 1-49%, ≥50%). Results: A consistent benefit in OS, PFS, PFS-2 and ORR was observed in the pem+plat+pembro treatment arm, compared to the pem+plat+placebo arm, irrespective of staging (M1a vs. M1b), number (≤ 3 vs. 3) of organ systems with lesions and severity of patient-reported symptoms (Table 1). Results by PD-L1 expression in the subgroups were generally consistent regardless of the level of expression. Conclusions: Pem+plat+pembro demonstrated consistent clinical benefit across all subgroups analysed regardless of baseline tumor burden. These results continue to support pem+plat+pembro as a standard of care in metastatic NSQ-NSCLC. |
| نوع الوثيقة: |
text |
| اللغة: |
unknown |
| العلاقة: |
https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138Test; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=15387445&id=doi:10.1158%2F1538-7445.AM2021-442&atitle=Pemetrexed+and+platinum+plus+pembrolizumab+in+patients+with+metastatic+non-squamous+non-small+cell+lung+cancer+by+tumor+burden+at+baseline%3A+A+post-hoc+efficacy+analysis+of+KEYNOTE-189&stitle=Cancer+Res.&title=Cancer+Research&volume=81&issue=13+SUPPL&spage=&epage=&aulast=Gadgeel&aufirst=Shirish&auinit=S.&aufull=Gadgeel+S.&coden=&isbn=&pages=-&date=2021&auinit1=S&auinitmTest= |
| الإتاحة: |
https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138Test |
| رقم الانضمام: |
edsbas.D74B2BF8 |
| قاعدة البيانات: |
BASE |
